The Evolution of TKIs in ROS1+ NSCLC

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss the prevalence of ROS1 fusions in non–small cell lung cancer.

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss treatment sequencing in ROS1-positive non–small cell lung cancer.

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss TKI selection in ROS1-positive non–small cell lung cancer.

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss CNS involvement in ROS1-positive non–small cell lung cancer.

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss data for taletrectinib in ROS1-positive non–small cell lung cancer.

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, on how FDA approval of taletrectinib would affect ROS1-positive non–small cell lung cancer management.

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, on novel approaches being investigated in ROS1-positive non–small cell lung cancer.